



18 June 2012

Insilico and Metabolomic Discoveries Launch Media Optimisation Kit and Cell Line Engineering Kit

(Potsdam/Stuttgart) – Metabolomic Discoveries and Insilico Biotechnology have launched two innovative products, jointly developed to optimise bioproduction processes: the Media Optimisation Kit and Cell Line Engineering Kit. The new kits will help industrial biotechnology companies to optimise the performance of their production strains.

These are the first fruits to be reaped from approx. six months of intensive cooperation between Metabolomic Discoveries GmbH based in Potsdam and Insilico Biotechnology AG based in Stuttgart. The two companies pooled their expertise and developed two new analysis kits which will help industrial biotechnology companies to optimise their cell cultures. Both kits can be used to analyse, predict and trim cellular processes for higher productivity and substrate efficiency.

The Media Optimisation Kit was developed to optimise the composition of nutrient solutions for mammalian cell lines such as CHO (Chinese Hamster Ovary) cells. In the field of biotechnology, these cells are often used for the production of recombinant proteins, e.g. for therapeutics. The Cell Line Engineering Kit is ideal for optimising microbial cultures (e.g. with *E. coli*), which are being used more and more frequently to produce bioproducts such as enzymes and fine chemicals. It was only possible to develop the kits by combining Metabolomic Discoveries platform for quantitative metabolite analysis systematically with Insilico's platform for simulating the metabolism and energy balance of cells. The result is a fast and reliable way of optimising economically relevant bioprocesses – not only in the development phase but also during production processes.

"Our jointly developed platform of predictive network models and absolute measurements of central metabolic compounds significantly reduces experimental complexity for improving the efficiency of biotechnological production processes, giving our customers a sharp competitive advantage", explains Klaus Mauch, Insilico's CEO. Nicolas Schauer, CEO of Metabolomic Discoveries GmbH, adds: "We are delighted to offer our clients an integrated and reliable one-stop solution for optimising metabolic processes in fermentations."

Press Release



Metabolomic Discoveries is a leading research and analytical service company. The company provides comprehensive metabolite analysis - metabolomics - in biological systems and the identification of biomarkers in plant, animal and microbial systems. In addition, the objective pursued by Metabolomic Discoveries is the qualitative improvement of food, beverages and bioprocesses by combining analytical and bioinformatics with biological expertise. For further information visit www.metabolomicdiscoveries.com.

Insilico Biotechnology is a market-leading company providing solutions and software for the simulation of living cells. An interdisciplinary team of experts offers customised solutions for the efficient manufacturing of biotechnological products and for the development of drug test systems by using high-performance computing and Insilico's proprietary software. For world-leading companies from the chemical and pharmaceutical industries, Insilico's technology lowers time, risk and costs of development processes. Founded in 2001, Insilico is a privately held company based in Stuttgart, Germany. For further information, please visit www.insilico-biotechnology.com.

Contact:

Metabolomic Discoveries GmbH
Dr. Nicolas Schauer,
T +49 331 951 43881
schauer@metabolomicdiscoveries.com
www.metabolomicdiscoveries.com

Insilico Biotechnology AG
Dr. Heike Lehmann | PR
T +49 711 460 594-18
F +49 711 460 594-10
heike.lehmann@insilico-biotechnology.com